Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BORID followed by rituximab maintenance in relapsed/refractory mantle cell lymphoma
2004-002150-64Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2004
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in mantle cell lymphoma (MCL), sponsored by Medical University of Vienna. Primary endpoint: Primary objective. Started Nov 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2004-002150-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002150-64.